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A B S T R A C T
Objective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical
practice given according to the marketing authorization.
Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracycline-
containing regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS).
Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5–7.3)
and 18.5 months (95%CI: 11.5–25.6), respectively. Median OS was significantly higher (P = 0.028) in patients
receiving trabectedin in ≤ 2nd line (25.3 months) than in ≥ 3rd (15.1 months) and with ECOG performance
status ≤ 1 at trabectedin start (19.8 months) than ECOG 2–3 (6.0 months, P = 0.013). When calculating OS
since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced
(30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy
(87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radio-
chemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients
(25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration
of 11 months (range: 4–93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR)
of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR
(50.0%) than those in ≥ 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines.
Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%).
Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure
to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable
safety profile.
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Uterine leiomyosarcoma (uLMS) is an uncommon condition that
accounts for approximately 1% of all uterine malignancies, and whose
annual incidence is 0.6 per 100,000 women (D'Angelo and Prat, 2010).
The uLMS is a very aggressive tumor, with a 5-year survival ranging
between 16% and 57% depending on the disease stage at diagnosis
(Kapp et al., 2008). In fact, the median overall survival in advanced or
recurrent disease is less than 12 months (Zivanovic et al., 2009). Sur-
gical resection is probably the only potential option for cure so far
(Korets and Curtin, 2012). Despite adequate surgical resection, 40–70%
of patients subsequently develop a recurrence (Arend et al., 2018).
Drugs for the treatment of uLMS include doxorubicin (objective re-
sponse rate [ORR]: 13–25%), ifosfamide (ORR: 17%), and gemcitabine
(ORR: 21%) (Look et al., 2004; Amant et al., 2015). Studies evaluating
the combination of gemcitabine and docetaxel have reported response
rates ranging between 27% and 53%, depending on the number of
previous chemotherapy lines (Hensley et al., 2002; Hensley et al., 2008;
Hensley et al., 2008). Other cytotoxic agents, such as temozolomide and
paclitaxel, have demonstrated more modest results (Gallup et al., 2003;
Anderson and Aghajanian, 2005).
Trabectedin (Yondelis®; PharmaMar, S.A., Madrid, Spain) is a nat-
ural drug derived from the marine tunicate Ecteinascidia turbinata and
currently produced synthetically (Monk et al., 2012). Trabectedin is
indicated for the treatment of adult patients with advanced soft tissue
sarcoma (STS) after failure of previous treatment with anthracycline
and ifosfamide or are not a candidate to receive them (European
Medicines Agency, 2019). The efficacy and manageable safety profile of
trabectedin for the treatment of advanced uLMS have been demon-
strated in diverse clinical trials (Monk et al., 2012; Hensley et al., 2017;
Gadducci et al., 2018; Pautier et al., 2015), retrospective studies
(Judson et al., 2010; Sanfilippo et al., 2011), and case series (Tewari
et al., 2006; Amant et al., 2009; Corrado et al., 2011; Payne et al., 2014;
Bongiovanni et al., 2015; Tavella et al., 2017; Nteli et al., 2018; Henry
et al., 2019). Gadducci et al. (2018) have recently reported the results
from a phase II study on the activity of the single-agent trabectedin
1.3 mg/m2 in 126 pretreated patients with metastatic or locally re-
lapsed uLMS. The study met the condition for trabectedin activity as
progression-free survival (PFS) rate after 6 months from the study
entry, i.e., the primary end-point of this study, was 35.2% (95% con-
fidence interval, CI 95%CI, 26.2–45) of patients with no difference in
PFS according with the number of previous chemotherapy lines. No-
teworthy, Hensley et al. (2017) conducted a post hoc subgroup analysis
of patients with uLMS pretreated with anthracycline-based therapy in
the pivotal phase III SAR-3007study (Demetri et al., 2016), which
evaluated the efficacy and safety of trabectedin vs. dacarbazine in pa-
tients with unresectable, locally advanced or metastatic liposarcoma or
leiomyosarcoma. Overall, 232 of 577 patients had uLMS and were
treated with trabectedin 1.5 mg/m2 by 24-hour intravenous infusion
(n = 144) or dacarbazine 1 g/m2 by 20–120-minute IV infusion
(n = 88) once every three weeks. PFS for trabectedin was 4.0 months
compared with 1.5 months for dacarbazine (hazard ratio [HR] = 0.57;
95% CI: 0.41–0.81; p = 0.012). Toxicity profile of trabectedin was si-
milar to that reported in the overall leiomyosarcoma and liposarcoma
population and were consistent with the known safety profile of tra-
bectedin. Additionally, a retrospective analysis of 66 previously-treated
unselected patients with metastatic uLMS treated with trabectedin
1.0 mg/m2 to 1.5 mg/m2 observed a partial response (PR) in eleven
(16%) patients, whereas 23 (35%) patients achieved stable disease (SD)
(Sanfilippo et al., 2011). Recorded responses as well as median PFS and
OS of 3.3 months and 14.4 months, respectively, were consistent with
those seen in more selective populations enrolled in clinical trials.
The aim of this retrospective analysis was to review the data of
patients with advanced uLMS treated with anthracycline-containing
regimens in tertiary hospitals across Spain to assess the efficacy of
trabectedin in real-life routine clinical practice according to SmPC.
2. Methods
2.1. Study design
This retrospective, observational, multicenter study involved pa-
tients who received trabectedin after an anthracycline-containing re-
gimen/s for uLMS. Eligible patients were patients ≥ 18 years old with
unresectable advanced or metastatic uLMS who had experienced either
relapse or disease progression at the time of starting trabectedin
treatment. All patients were treated between September 17th, 2007 and
April 30th, 2016 with at least three cycles of trabectedin, administered
according to the marketing authorization at a recommended dose of
1.5 mg/m2 through a central venous line as a 24-h continuous infusion
every 3 weeks. In accordance with the Summary of Product
Characteristics (SmPC) (European Medicines Agency, 2019), other
eligibility criteria included adequate baseline renal, hepatic and bone
marrow function according to laboratory standard parameters before
the first treatment cycle and complete recovery from any toxicity de-
rived from prior treatment/s. The only exclusion criterion was not
having available information from the medical record. As per SmPC
patients treated in 1st-line of advanced disease with trabectedin were
not candidates to receive more anthracyclines after having been treated
with these drugs in the adjuvant setting. In the present manuscript, first
Table 1
Demographic and clinical information of patients, and treatments.
Patients (n = 36)
AT DIAGNOSIS
Age, median years (range) 54 (29–68)
Disease, n (%)
Localized 19 (52.8)
Locally advanced 4 (11.1)
Metastatic 13 (36.1)
Tumor size, n (%) *
< 50 mm 5 (17.9)
≥50 mm 23 (82.1)
Histologic grade, n (%) *
Low 7 (28.0)
High 18 (72.0)
Mitotic index, n (%) *
0–15/10 HPF 11 (50.0)
> 15/10 HPF 11 (50.0)
PREVIOUS TREATMENTS




Chemotherapy prior to trabectedin (any line for relapsed
disease), n (%)
30 (83.3)
Number of lines, median (range) 2 (0–3)




Age at onset of trabectedin treatment, median years (range) 57 (36–70)
ECOG performance status at starting treatment, n (%) *
0–1 28 (87.5)
2–3 4 (12.5)
Number of trabectedin cycles, median (range) 6 (3–25)
Reasons for trabectedin discontinuation, n (%)
Tumor progression 30 (83.3)
Intolerance 3 (8.3)
Complete tumor response 1 (2.8)
Patient’s decision 1 (2.8)
Physician’s decision 1 (2.8)
ECOG, Eastern Cooperative Oncology Group; HPF, high-power fields
* Data not available for some patients.
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line of treatment in advanced disease represents the first systemic
therapy in this setting, regardless adjuvant chemotherapy. All women
signed the written consent to participate in the study, except for those
who died before the analysis or who were not possible to contact.
Procedures were in accordance with the Declaration of Helsinki and
approved by Ethics Committees according to national legislation.
2.2. Endpoints and variables
The primary endpoint included the efficacy of trabectedin in re-
lapsed/metastatic disease, as defined by PFS. The PFS was defined as
the elapsed time between the date of starting trabectedin treatment
(first dose) and disease progression or death, by any cause. Secondary
endpoints included the OS, the determination of the best tumor re-
sponse to trabectedin (with the special attention to the number of
treatment line in advanced disease), and the safety profile of
Fig. 1. Progression-free survival and overall survival since starting trabectedin treatment, in all patients and considering the line of treatment in advanced disease.
Table 2
Survival analysis considering characteristics of patients or treatments.
Since trabectedin treatment Since diagnosis
Progression-free survival P Overall survival P Overall survival P
Median line of trabectedin treatment of advanced disease
1st-2nd (n = 15) 5.4 (0.0–11.1) 0.470 25.3 (0.0–66.7) 0.028 87.4 (22.6–152.1) 0.310
3rd or successive (n = 21) 5.7 (3.8–7.7) 15.1 (10.9–19.2) 44.7 (42.4–47.0)
ECOG at trabectedin start *
0–1 (n = 28) 5.4 (3.7–7.0) 0.260 19.8 (12.9–26.7) 0.013 46.0 (32.7–59.9) 0.930
2–3 (n = 4) 3.1 (1.7–4.5) 6.0 (2.4–9.6) 30.0 (28.1–31.9)
Disease at diagnosis
Localized (n = 19) 3.1 (0.0–6.9) 0.410 21.1 (11.1–31.2) 0.130 87.4 (28.2–146.5) 0.041
Locally advanced (n = 4) 3.0 (1.4–4.6) 4.1 (0.4–7.9) 30.0 (0.0–68.8)
Metastatic (n = 13) 6.8 (3.9–9.8) 18.5 (8.0–29.1) 44.0 (19.4–68.6)
Adjuvant therapy
Yes (n = 21) 4.6 (0.6–8.6) 0.830 19.8 (11.9–27.8) 0.170 87.4 (25.8–148.9) 0.003
No (n = 15) 5.9 (3.3–8.6) 15.1 (0.0–30.9) 30.0 (3.9–56.2)
Type of adjuvant therapy
Radiotherapy (n = 10) 5.7 (0.0–15.0) 0.088 21.8 (7.8–35.8) 0.370 87.4 (21.9–152.8) 0.027
Chemotherapy (n = 5) 13.6 (0.0–33.0) 18.5 (10.4–26.7) 63.7 (25.7–101.8)
Both (n = 6) 2.9 (2.2–3.6) 8.5 (3.6–13.4) 106.7 (0.0–235.6)
Values are expressed as median (range). ECOG, Eastern Cooperative Oncology Group.
* Data not available for 4 patients.
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trabectedin. The OS was calculated as the elapsed time between the
date of starting trabectedin treatment (first dose) and death, by any
cause. Tumor response was assessed following the Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 (Eisenhauer et al., 2009).
The ORR was calculated as the sum of complete response (CR) and PR,
whereas DCR as the sum of CR, PR, and SD. The adverse events (AEs)
were evaluated according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0.
2.3. Statistical analysis
Continuous variables were expressed as median and ranges;
whereas categorical ones as absolute and relative frequencies (%).
Comparison in tumor response to trabectedin regarding the line in
advanced disease was performed by an X-square test. Time-to-event
endpoints (PFS and OS) and their fixed-time estimations were estimated
according to the Kaplan–Meier method and comparisons of survival
curves considering characteristics of patients and treatments were done
using the log-rank test. Multivariate survival analysis was performed by
using Cox regression. The statistical significance was established when
P = 0.05. All statistical procedures were carried out by using SPSS
version 20 and all data were obtained from medical records.
3. Results
3.1. Characteristics of patients and treatments
Thirty-six patients with metastatic uLMS from 11 Spanish tertiary
hospitals were included in the study (Table 1). At diagnosis, patients
had a median age of 54 years (range: 29–68), mostly with an Eastern
Cooperative Oncology Group (ECOG) performance status 0–1 (92.9%),
tumor size≥ 50 mm (82.1%), and high-grade disease (72.0%). Twenty-
one patients (58.4%) received adjuvant therapy, mainly radiotherapy
(27.8%), chemotherapy (13.9%), or both (16.7%). A total of 34 patients
(out of 36) underwent a hysterectomy for the primary tumor. In the
remaining 2 patients, hysterectomy was contraindicated by the meta-
static disease. Thirty patients (83.3%) treated with trabectedin had
received prior chemotherapy for relapsed disease (median number of
lines 2; range 0–3). Six patients had not received any chemotherapy line
before trabectedin since they were not candidates to receive more an-
thracyclines after having been treated with these drugs in the adjuvant
setting. The median number of trabectedin cycles was 6 (range: 3–25).
Reasons for trabectedin discontinuation included: tumor progression
(n = 30), patient’s decision (n = 1), physician’s decision (n = 1), CR
(n = 1), and unacceptable toxicity (hematological toxicity in two pa-
tients, and hepatic one in one patient).
3.2. Efficacy
After a median follow-up of 33 months (range: 7–93), median PFS
and OS since starting trabectedin treatment were 5.4 months (95%CI:
3.5–7.3; Fig. 1A) and 18.5 months (95%CI: 11.5–25.6; Fig. 1C), re-
spectively. No differences in PFS were found between trabectedin ad-
ministered in 1st–2nd lines of advanced disease, and 3rd and successive
Table 3
Best tumor response to trabectedin.
Tumor response, n (%)
CR PR SD PD ORR DCR P
Overall (n = 36) 1 (2.8%) 9 (25.0%) 18 (50.0%) 8 (22.2%) 10 (27.8%) 28 (78.8%)
Trabectedin line of advanced disease
1st line (n = 6) 1 (16.7%) 3 (50.0%) 1 (16.7%) 1 (16.7%) 4 (66.7%) 5 (83.4%) 0.041
2nd or successive lines (n = 30) 0 (0.0%) 6 (20.0%) 17 (56.7%) 7 (23.3%) 6 (20.0%) 23 (76.7%)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate.
Table 4
Adverse events associated with trabectedin treatment.
Adverse event, n (%) Hematological toxicity
Overall Grade 1/2 Grade 3/4
Neutropenia 11 (30.5) 4 (11.1) 7 (19.4)
Anemia 9 (25.0) 7 (19.4) 2 (5.6)
Febrile neutropenia 2 (5.6) 0 (0.0) 2 (5.6)
Thrombocytopenia 1 (2.7) 0 (0.0) 1 (2.7)
Non-hematological toxicity
Fatigue 9 (25.0) 8 (22.2) 1 (2.7)
Nausea 5 (13.9) 5 (13.9) 0 (0.0)
Vomiting 4 (11.1) 4 (11.1) 0 (0.0)
Diarrhea 2 (5.6) 2 (5.6) 0 (0.0)
Decreased appetite 2 (5.6) 2 (5.6) 0 (0.0)
Elevation in ALT 2 (5.6) 2 (5.6) 0 (0.0)
Elevation in AST 1 (2.7) 1 (2.7) 1 (2.7)
Constipation 1 (2.7) 1 (2.7) 0 (0.0)
Myalgia 1 (2.7) 1 (2.7) 0 (0.0)
Hypotension 1 (2.7) 1 (2.7) 0 (0.0)
Hypocalcemia 1 (2.7) 1 (2.7) 0 (0.0)
Mucositis 1 (2.7) 1 (2.7) 0 (0.0)
Infection 1 (2.7) 0 (0.0) 1 (2.7)
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Table 5
Relevance of our results as compared with prospective clinical data obtained in patients with uLMS.
Studies Number of patients
(n)










Median PFS (months) Median OS (months)
Phase II study
Gadducci et al. 2018
115* 57
(34–76)
100.0 7.0 16.5 23.4 60.8 4.1 20.6
Phase III study
Hensley et al. 2017
232 54
(27–81)
100.0 0.0 11.0 11.0 31.0 4.0 13.4
Real-world outcomes
Rubio et al. 36 54
(29–68)
92.9 2.8 25.0 27.8 77.8 5.4 18.5
CR, complete response; DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group; ORR, overall response rate; OS, overall survival; PFS; progression-free
survival; PR, partial response; PS, performance status.
* Population per protocol.
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lines (Fig. 1B). In contrast, median OS for patients receiving trabectedin
in 1st or 2nd line in advanced disease (25.3 months, 95%CI: 0.0–66.7)
was significantly higher than in ≥ 3rd line/s (15.1 months, 95%CI:
10.9–19.2; P = 0.028; Fig. 1D). Furthermore, the median OS was sig-
nificantly longer in patients with ECOG performance status 0–1 at
trabectedin start (19.8 months, 95%CI: 12.9–26.7) than ECOG 2–3
(6.0 months, 95%CI: 2.4–9.6; P = 0.013). When calculating OS since
diagnosis patients with localized disease at diagnosis had longer OS
(87.4 months, 95%CI: 28.2–146.5) compared with locally advanced
(30.0 months, 95%CI: 0.0–68.8) and metastatic disease (44.0 months,
95%CI: 19.4–68.6; P = 0.041). Additionally, patients who received
adjuvant therapy had a longer OS (87.4 months, 95%CI: 25.8–148.9)
compared with those who did not (30.0 months, 95%CI: 3.9–56.2;
P = 0.003), especially when receiving radiotherapy and chemotherapy
(106.7 months, 95%CI: 0.0–235.6; P = 0.027) (Table 2). One patient
(2.8%) had a CR and nine patients (25.0%) achieved a PR for an ORR of
27.8% with a median response duration of 11 months (4–93; Table 3).
Eighteen patients (50.0%) had SD for a DCR of 77.8%. Tumor responses
to trabectedin were significantly different (P = 0.041) regarding the
line in advanced disease. More patients receiving trabectedin in 1st line
of advanced disease achieved CR (16.7%) and PR (50.0%) than those
in ≥ 2nd line/s (0.0% and 20.0%, respectively). Similarly, fewer pa-
tients in 1st of advanced disease line had SD (16.7%) and PD (16.7%)
than in ≥ 2nd line/s (56.7% and 23.3%). The DCR was similar across
treatment lines (83.4% in 1st line of advanced disease vs. 76.7%
in ≥ 2nd line/s).
3.3. Safety
Treatment-emergent AEs observed were consistent with established
safety and toxicity profiles of trabectedin. Most frequent hematological
AES were reversible neutropenia (11 patients, 30.5%), mainly grade 3/
4 (7 patients, 19.4%), and anemia (9 patients, 25.0%), especially grade
1/2 (7 patients, 19.4%), whereas most frequent non-hematological AEs
included fatigue (25.0%), nausea (13.9%), and vomiting (11.1%)
(Table 4).
4. Discussion
Results from clinical studies have demonstrated that trabectedin is
an appropriate second-line option for advance uLMS as it provides long-
term tumor stabilization and good tolerability (Hensley et al., 2017;
Gadducci et al., 2018; Hindi and Martin-Broto, 2017). Although ran-
domized controlled clinical trials are the gold standard of medical
evidence, their applicability to daily clinical practice and general-
izability to diverse patient populations needs to be verified in non-in-
terventional studies to gain real-life validity. Despite the fact that the
eligibility criteria of this study were less restrictive than those of pro-
spective clinical trials, the patients were treated according to the terms
of the marketing authorization. Thus, the results from our study are
representative of patient demographics, clinical practice, and outcomes
in the real-life practice across Spain.
In the present study patients’ baseline demographic and disease
characteristics were comparable with those included in the randomized
phase II/III studies (Hensley et al., 2017; Gadducci et al., 2018)
(Table 5). In our study, trabectedin administration resulted in an ORR
of 27.8%, and a median PFS (primary end-point) and OS of 5.4 and
18.5 months, respectively. Recognizing that comparisons cannot be
established, and only with the aim of putting the findings in wider
context, the benefit in PFS and OS in this analysis was particularly si-
milar to those observed in the phase II study, which reported a median
PFS of 4.1 and a median OS of 20.6 months, respectively (Gadducci
et al., 2018). In addition, similar as observed in the phase II study we
observed no difference in PFS according to the number of previous
chemotherapy lines (Gadducci et al., 2018). In our retrospective, real-
life analysis the benefit of trabectedin in PFS was also supported by
other secondary endpoints as trabectedin therapy resulted in higher
than expected ORR (27.8%) and DCR (77.8%), which compares fa-
vorably with previous clinical study reports (Table 5). It is necessary to
indicate that in our study the evaluation of trabectedin was carried out
after 3 cycles of treatment, in agreement with previous studies sug-
gesting a delated response by trabectedin (Sanfilippo et al., 2011; Le
Cesne et al., 2005; Grosso et al., 2007; Le Cesne et al., 2015; Endo et al.,
2020).On the other hand, trabectedin-related AEs experienced by our
patients were in concordance with extensive prior experience and re-
ports reflecting the well-characterized transient and non-cumulative
toxicities of bone marrow suppression and hepatotoxicity (Le Cesne
et al., 2015; Samuels et al., 2013). In our study, the patients received a
median of 6 trabectedin cycles, suggestive of an acceptable safety
profile that allowed prolonged treatment up to 25 cycles. No new or
unexpected adverse reactions or qualitative differences in the adverse
reactions were observed.
Regarding major limitation of this analysis, the retrospective nature
and the low number of participating women were the main weaknesses
of the study. Therefore, our results should be interpreted with caution
as they may be subject to bias.
In conclusion, trabectedin confers clinical benefit in patients with
recurrent/metastatic uLMS, after failure to an anthracycline-containing
regimen, especially when administered in earlier lines, with the man-
ageable safety profile of trabectedin. Real-life results from the present
study are largely comparable to previously shown in clinical studies.
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